<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902018000400357</article-id>
<article-id pub-id-type="doi">10.29262/ram.v65i4.367</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio de seguridad en inmunoterapia: práctica clínica en consulta de alergia]]></article-title>
<article-title xml:lang="en"><![CDATA[Study on immunotherapy safety: clinical practice in allergy outpatient care]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tomás-Pérez]]></surname>
<given-names><![CDATA[Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Cavero]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Ortega]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario La Paz  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>65</volume>
<numero>4</numero>
<fpage>357</fpage>
<lpage>361</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902018000400357&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902018000400357&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902018000400357&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  La inmunoterapia con alérgenos específicos es el único tratamiento modificador del sistema inmunológico para la enfermedad alérgica.  Objetivo:  Identificar la prevalencia de reacciones adversas durante la fase de inicio de inmunoterapia subcutánea en condiciones de vida real y los posibles factores de riesgo que se asociados.  Métodos:  Estudio observacional retrospectivo de un año. Se registraron características epidemiológicas de 481 pacientes, inmunoterapia utilizada y reacción adversa.  Resultados:  16.8 % de los pacientes sufría dermatitis atópica, 8.9 % alergia alimentaria, 4 % alergia a fármacos y 7.3 % había presentado urticaria idiopática. El polen de gramíneas fue el principal alérgeno. En los pacientes polisensibilizados, el uso de extractos polimerizados que llevaban gramíneas en su composición fue mayor (89.2 %) que los extractos nativos (78.9 %). Se administraron 1292 dosis de inmunoterapia específica: 881 extractos polimerizados y 411 extractos depot; 30 pacientes presentaron reacción adversa (6.2 %): 4.4 % de quienes recibieron extracto polimerizado y 14.3 % de quienes recibieron uno nativo (RM = 3.657). En los pacientes que recibieron extractos polimerizados, la reacción adversa fue local en 82.4 %, en 11.8 % sistémica leve y solo uno, sistémica grave; 66.7 % de quienes recibieron extracto nativo presentó reacciones locales, 25 % sistémicas leves y solo uno, sistémica grave.  Conclusión:  La inmunoterapia subcutánea en condiciones de vida real no está libre de riesgo, pero la incidencia de reacciones graves es muy baja, especialmente con extractos polimerizados, incluso cuando se utilizan tratamientos agrupados o ultrarrápidos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Immunotherapy with specific allergens is the only immune system-modifying treatment for allergic disease.  Objective:  To identify the prevalence of adverse reactions during the subcutaneous immunotherapy initiation phase in real-life conditions and possible associated risk factors.  Methods:  One-year retrospective, observational study. Epidemiological characteristics of 481 patients, type of immunotherapy used and adverse reactions were recorded.  Results:  16.8% of patients suffered atopic dermatitis, 8.9% food allergy, 4% drug allergy and 7.3 % had experienced idiopathic urticaria. Grass pollen was the main allergen. In polysensitized patients, the use of polymerized extracts that contained grasses in their composition was higher (89.2%) than that of native extracts (78.9%). A total of 1292 doses of specific immunotherapy were administered: 881 polymerized extracts and 411 depot extracts; 30 patients had an adverse reaction (6.2 %): 4.4% of those who received polymerized extract and 14.3 % of those who received a native one (OR = 3.657). In patients who received polymerized extracts, the adverse reaction was local in 82.4%, mild systemic in 11.8% and only in one it was serious systemic; 66.7 % of those who received native extract had local reactions, 25 % mild systemic and only one, serious systemic.  Conclusion:  Subcutaneous immunotherapy under real life conditions is not free of risk, but the incidence of severe reactions is very low, especially with polymerized extracts, even when grouped or ultra-rapid testing is used.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Seguridad]]></kwd>
<kwd lng="es"><![CDATA[Inmunoterapia]]></kwd>
<kwd lng="es"><![CDATA[Reacción adversa]]></kwd>
<kwd lng="en"><![CDATA[Safety]]></kwd>
<kwd lng="en"><![CDATA[Immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[Adverse reaction]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez-Ortega]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cimarra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Henríquez-Sanrana]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol.]]></source>
<year>2017</year>
<volume>27</volume>
<numero>^sSuppl. 1</numero>
<issue>^sSuppl. 1</issue>
<supplement>Suppl. 1</supplement>
<page-range>1-35</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asamoah]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kakourou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dhami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Agache]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Muraro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews]]></article-title>
<source><![CDATA[Clin Transl Allergy]]></source>
<year>2017</year>
<volume>7</volume>
<numero>25</numero>
<issue>25</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jutel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Agache]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bonini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Burks]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Calderon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Consensus On (ICON) Allergy Immunotherapy (AIT)]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>2015</year>
<volume>136</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>556-68</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casanovas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Caldas]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts]]></article-title>
<source><![CDATA[Clin Exp Allergy.]]></source>
<year>2007</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>434-40</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Michel]]></surname>
<given-names><![CDATA[FB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety considerations in assessing the role of immunotherapy in allergic disorders]]></article-title>
<source><![CDATA[Drug Saf.]]></source>
<year>1994</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-17</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nettis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tursi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic reactions to allergen immunotherapy: a review of the literature]]></article-title>
<source><![CDATA[Immunopharmacol Immunotoxicol.]]></source>
<year>2003</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Justicia]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cimarra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Távora]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Orovitg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol.]]></source>
<year>2009</year>
<volume>102</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accelerated immunotherapy schedules: review of efficacy and safety]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2006</year>
<volume>97</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>126-37</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quirce]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dávila]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Ortega]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergic respiratory disease: Different allergens, different symptoms]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2017</year>
<numero>72</numero>
<issue>72</issue>
<page-range>1306-16</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Del Río]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Just]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pfaar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Tabar]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2017</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>462-72</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
